ENDOCAN-TUTHYREF guidelines. Locoregional therapies for locally advanced and/or metastatic thyroid cancer.
1/5 보강
This article presents consensus recommendations by a multidisciplinary panel of endocrinologists, medical oncologists, pathologists, radiation oncologists, surgeons and nuclear medicine physicians.
APA
Jannin A, Escande A, et al. (2025). ENDOCAN-TUTHYREF guidelines. Locoregional therapies for locally advanced and/or metastatic thyroid cancer.. Annales d'endocrinologie, 86(4), 101790. https://doi.org/10.1016/j.ando.2025.101790
MLA
Jannin A, et al.. "ENDOCAN-TUTHYREF guidelines. Locoregional therapies for locally advanced and/or metastatic thyroid cancer.." Annales d'endocrinologie, vol. 86, no. 4, 2025, pp. 101790.
PMID
40379205
Abstract
This article presents consensus recommendations by a multidisciplinary panel of endocrinologists, medical oncologists, pathologists, radiation oncologists, surgeons and nuclear medicine physicians. The recommendations specifically address iodine-refractory well-differentiated thyroid carcinoma and locally advanced and/or metastatic medullary thyroid carcinoma. Treatment algorithms based on risk-benefit assessments of various multimodal therapeutic approaches are proposed for each clinical scenario. Given the limited data available on the management of these rare but aggressive forms of thyroid cancer, these consensus recommendations provide essential guidance for multidisciplinary teams to ensure optimal care for patients with these complex thyroid carcinomas.
MeSH Terms
Humans; Carcinoma, Neuroendocrine; Combined Modality Therapy; Iodine Radioisotopes; Neoplasm Metastasis; Thyroid Neoplasms